Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-06

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to identify healthcare workers with SARS CoV 2 antibodies who have not been previously diagnosed and are presumed COVID-19 negative, then determine the level of immunity in this population which could inform further decisions about widespread antibody testing in a healthcare worker population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COVID-19 Antibody and Reinfection Study

NCT05365750

COVID-19 Testing

COMPLETED

COVID-19 Antibodies Among Healthcare Workers

NCT04425889

COVID-19 SARS-CoV 2

COMPLETED

Antibodies Responses to COVID-19 Infection in Hospitalized Patients

NCT04520880

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection) Hospitalized Patients Laboratory-confirmed SARS-CoV 2 Infection

UNKNOWN

Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants

NCT05858502

COVID-19

RECRUITING NA

Seroprevalence of MERS-CoV IgG in Healthcare Workers

NCT02497885

Coronavirus Infections

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Enrolled participants will complete a survey gauging their level of confidence they will be antibody positive. Participants will then complete serologic testing for SARS CoV 2 IgG antibodies. The study will characterize the prevalence of antibody positivity in this population and assess whether there is a correlation between a pre-test confidence level using a Likert scale and actual antibody positivity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV 2 COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Serologic Arm

Enrolled participants will have COVID19 IgG antibody testing performed.

Group Type OTHER

Serologic testing

Intervention Type OTHER

COVID19 IgG antibody testing to be performed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Serologic testing

COVID19 IgG antibody testing to be performed

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years old.
* Mayo Clinic employee in procedural and surgical area.
* Suspected COVID-19 exposure.
* Completed PCR test twice with negative results.